Clinical trial
A Trial for Patients With Advanced/Recurrent Cervical Cancer
NCT00190983 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190983 |
|---|---|
| Title | A Trial for Patients With Advanced/Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 29 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 20, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: